CTGCT - Centre of Excellence for the Technologies of Gene and Cell Therapy

CTGCT - 基因和细胞治疗技术卓越中心

• 批准号: 10069462
• 金额: $ 100.44万
• 依托单位: UNIVERSITY COLLEGE LONDON
• 依托单位国家: 英国
• 项目类别: EU-Funded
• 财政年份: 2023
• 资助国家: 英国
• 起止时间: 2023 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10069462
• 关键词: CTGCT; Centre; Excellence; Technologies; Gene

Scientific discoveries on mechanisms of biomedical processes and invention of technologies to repair disease-related genes or destroy cancer cells represent the foundation of an important pillar of personalized medicine. The new Centre of Excellence for the Technologies of Gene and Cell Therapy (CTGCT) will be the first Centre of Excellence in biomedicine in Slovenia and unique with an approach combining mammalian cell synthetic biology and immunology to develop novel technologies for the development of GCTs and cancer immunotherapy in the EU and beyond. The aim of CTGCT is to become one of the leaders in the interdisciplinary breakthrough science technologies for GCT and a model for international research excellence, industrial collaboration and public engagement. CTGCT will gain a competitive edge based on the vertical integration of the technologies for whose further development the foundations have been laid at the National Institute of Chemistry (SI), and with support of expertise and knowledge of the advanced partners University College London (UK), University Medical Centre Utrecht (NL), Charité – Universitätsmedizin Berlin (DE) and Technical University Dresden (DE). Supported by the involvement of clinicians and patient organizations, CTGCT will enable translation of research achievementsinto therapeutic applications, primarily neurological and rare genetic diseases and cancer immunotherapy, and establish a capacity to prepare the GMP clinical grade therapeutic reagents, which is currently a bottleneck to effective translation. By bridging gap in translation, CTGCT will facilite high impact of excellent research and innovation on health in Slovenia as well as in the West Balkans, East Europe and beyond. It will strengthen scientific capabilities and long-term collaborations with partners and others leading scientific institutions from abroad, as well as improve accessibility of the GCTs.

对生物医学过程机制的科学发现，以及修复疾病相关基因或摧毁癌细胞的技术的发明，是个性化医学的重要支柱的基础。新的基因和细胞治疗技术英才中心(CTGCT)将是斯洛文尼亚的第一个生物医学英才中心，是独一无二的，其方法是结合哺乳动物细胞合成生物学和免疫学，为欧盟和其他地区的GCTS和癌症免疫疗法的开发开发新技术。CTGCT的目标是成为GCT跨学科突破性科学技术的领导者之一，并成为国际卓越研究、产业合作和公众参与的典范。CTGCT将在技术的垂直整合的基础上获得竞争优势，这些技术的进一步发展的基础已经在国家化学研究所(SI)奠定了基础，并在高级合作伙伴伦敦大学学院(英国)、乌得勒支大学医学中心(NL)、柏林夏洛特大学(DE)和德累斯顿工业大学(DE)的专业知识的支持下获得了竞争优势。在临床医生和患者组织的参与下，CTGCT将能够将研究成果转化为治疗应用，主要是神经和罕见的遗传病和癌症免疫疗法，并建立制备GMP临床级治疗试剂的能力，这目前是有效转化的瓶颈。通过弥合翻译方面的差距，CTGCT将促进出色的研究和创新对斯洛文尼亚以及西巴尔干、东欧和其他地区的卫生事业产生重大影响。它将加强科学能力以及与合作伙伴和其他国外领先科研机构的长期合作，并改善全球技术合作系统的可及性。